Effect of <scp>iGlarLixi</scp> on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RAs, 16 weeks of treatment with iGlarLixi significantly improved TIR and reduced TAR without severe hypoglycaemia.
Authors
- Alexandria Ratzki‐Leewing (ORCID: https://orcid.org/0000-0002-9474-7900)
- Viral N. Shah (ORCID: https://orcid.org/0000-0002-3827-7107)
- Luigi Meneghini (ORCID: https://orcid.org/0000-0003-4539-2725)
- Terry Dex
- Juan P. Frías (ORCID: https://orcid.org/0000-0001-9486-1255)
- Amélie Rodrigues
Institutions
- Western University (CA)
- University of Maryland, Baltimore (US)
- Foundation for the National Institutes of Health (US)
- Sanofi (United States) (US)
- Fusion (United States) (US)
- Fusion Academy (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1111/dom.16214
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Sanofi